U.S. pharma big copyright scrapped two experimental weight loss tablets previous calendar year—a at the time-day-to-day tablet, lotiglipron, due to elevated liver enzymes and also a two times-day-to-day capsule, danuglipron, resulting from sturdy Unwanted effects—but CEO Albert Bourla has explained the company is determined to “Engage in and